Delcath Systems, Inc.

24.09.2011 – 00:03
Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
New York and Stockholm (ots/PRNewswire) - March 2011 Data Confirm Strong Treatment Effect of Chemosaturation Delcath Systems announced today that James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine, will present updated investigator results from the Phase 3 ...
mehr
13.09.2011 – 08:32
Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
New York and Munich (ots/PRNewswire) - Chemosaturation Demonstrates Clinically Meaningful Tumor Response with Unresectable Neuroendocrine Tumors in the Liver Delcath Systems, Inc. announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and ...
mehr